retatrutide autoimmune disease Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide—A Game Changer in Obesity

Data are presented as a percentage of MTP protein expression versus the loading control GAPDH ( n = 3)

Choose peptides backed by research: Choose peptides with scientific backing and documented results to ensure youre investing in products with real potential

In the STEP 1 trial, approximately 44% of participants in the Wegovy group reported nausea at some point during treatment

GLP-1 medications typically begin at low doses and titrate upward over several weeks

Because of this titration, its normal for initial weight loss to be modest

In clinical trials, patients using Wegovy successfully lost up to 20% of their total body weight